50 people received COVAXIN; results encouraging: Trial principal investigator
The principal investigator of the vaccine trial team at Post-Graduate Institute (PGI) of Medical Sciences, Rohtak, Dr. Savita Verma, told ANI, "First part of phase I of vaccine trial has been completed. 50 people across India were administered the vaccine and the results were encouraging."
Human trials of COVAXIN had commenced at PGI Rohtak on July 17 when three volunteers received the potential vaccine.
In the first phase, 375 people across India were to be administered COVAXIN. In the first part of phase I trials, 50 people across India were to receive the potential vaccine to assess its safety, which has been completed, Dr. Verma said.
According to ANI, under the second part of phase I trials, six people were administered COVAXIN on Saturday.
The second phase of trials would include 750 volunteers across the 12 sites. All volunteers who will be recruited will be in the age group 12-65 years.
AIIMS Director and leading pulmonologist, Dr. Randeep Guleria had earlier said, "In the first phase, we see the safety of the vaccine which is of primary importance and the dose range is also calculated."